Hemab Therapeutics shares are trading higher after HC Wainwright & Co. initiated its coverage on the stock with a Buy rating and announced a price target of $40.

Benzinga Newsdesk www.benzinga.com Positive 94.4%

Neg 0% Neu 0% Pos 94.4%

Comments

No comments yet. Be the first!